

**AMENDMENTS TO THE CLAIMS**


**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**



1. (canceled).

2. (canceled).

3. (currently amended): The compound according to claim 2, which is A compound represented by formula ~~(I-1)~~ (A-1-1) or (A-1-2):



~~wherein all symbols have the same meanings as in claim 1 or 2.~~



wherein L<sup>1</sup> is a binding bond, a nitrogen atom, an oxygen atom, a sulfur atom which may be oxidized or C1-4 alkylene,

T<sup>1</sup> is a hydrogen atom(s) or a substituent(s),

k1 is 0 or an integer of 1-4,

T is a substituent(s).


E is a binding bond or a spacer of which main chain has an atom number of 1-8, and

Q is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s).

a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof.

4. **(canceled).**


5. **(currently amended):** The compound according to claim 3, which is a compound represented by formula (I-1-1):



wherein U is a binding bond, C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene,

ring G is a carbocyclic ring which may have a substituent(s) or a heterocyclic ring which may have a substituent(s),

E<sup>1</sup> is




wherein a left-pointing arrow is binding to a-position; a right-pointing arrow is binding to ring Q<sup>1</sup>; J<sup>1</sup> and J<sup>2</sup> are each independently a hydrogen atom or a substituent, and; M is a binding bond or C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene, and

ring Q<sup>1</sup> is a cyclic group which may have a substituent(s), ~~and~~

~~other symbols have the same meanings as in claim 2 or 4.~~


6. **(currently amended):** The compound according to claim 3, which is a compound represented by formula (I-1-2):



wherein R<sup>1</sup> is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s),

$L^2$  is a binding bond, a nitrogen atom or C1-4 alkylene, ~~the other symbols have the same meanings as in claim 2, 4 or 5~~

$E^1$  is




wherein a left-pointing arrow is binding to a-position; a right-pointing arrow is binding to ring  $Q^1$ ;  $J^1$  and  $J^2$  are each independently a hydrogen atom or a substituent, and; M is a binding bond or C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene,

ring  $Q^1$  is a cyclic group which may have a substituent(s), and

wherein N-phenyl-N'-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)urea is excepted.

7. **(currently amended):** The compound according to claim 5 or 6, wherein  $E^1$  is



~~wherein all symbols have the same meanings as in claim 5.~~

8. **(currently amended):** The compound according to claim 5-~~or~~6, wherein L<sup>1</sup> is a nitrogen atom, a sulfur atom which may be oxidized, or C1-4 alkylene.

9. **(original):** The compound according to claim 3, which is

- (1) N-[2-(4-chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-(4-fluorophenyl)acetamide,
- (2) N-[2-(4-chlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-phenylacetamide,
- (3) N-(2-*tert*-butyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-2-phenylacetamide,
- (4) 2-phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide,
- (5) 2-(4-fluorophenyl)-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide,
- (6) N-[2-(4-chlorophenyl)-5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-fluorophenyl)acetamide, or
- (7) *tert*-butyl 2-(4-chlorophenyl)-3-{[(4-fluorophenyl)acetyl]amino}-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-carboxylate.

10. **(currently amended):** A pharmaceutical composition comprising a compound represented by formula (A-1-1) or (A-1-2)~~(1)~~ according to claim 1~~3~~, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

11. **(original):** The pharmaceutical composition according claim 10, which is a preventive and/or therapeutic agent for mitochondrial benzodiazepine receptor mediated disease.

12. **(original):** The pharmaceutical composition according to claim 11, wherein a mitochondrial benzodiazepine receptor mediated disease is a disease caused by stress.

13. **(original):** The pharmaceutical composition according to claim 12, wherein a disease caused by stress is a central nervous system disease caused by stress, a respiratory system disease caused by stress and/or digestive system disease caused by stress.

14. **(original):** The pharmaceutical composition according to claim 13, wherein a central nervous system caused by stress is anxiety-related disease, sleep disorder, depression and/or epilepsy, a respiratory system disease caused by stress is asthma, a digestive system disease caused by stress is irritable bowel syndrome.

15. **(currently amended):** A pharmaceutical composition combining of the compound represented by formula (A-1-1) or (A-1-2)~~(I)~~ according to claim ~~13~~, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof and one kind or more kind selected from antianxiety drugs, antidepressant drugs, antiparkinson drugs, therapeutic drugs for schizophrenia, antiepileptic drugs, therapeutic drugs for asthma, therapeutic drugs for peptic ulcer, adjustive drugs for gastrointestinal function, antidiarrheals, evacuants, antihypertensive drugs, antiarrhythmic drugs, inotropic drugs and therapeutic drugs for urination disorder.

16. **(currently amended):** A method for prevention and/or treatment for a mitochondrial benzodiazepine receptor mediated disease in a mammal, which comprises administering to a mammal an effective dose of the compound represented by formula (A-1-1) or (A-1-2)~~(I)~~ according to claim ~~13~~, a salt thereof, an N-oxide, a solvate or a prodrug thereof.

17. **(canceled).**